eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2024
vol. 41
 
Share:
Send email
Share:
abstract:
Review paper

Systematic review and network meta-analysis of the risk of malignancy with biologic therapies and selective Janus kinase-1 inhibitors in atopic dermatitis

Daud Manzar
1
,
Nikhil Nair
1
,
Emmanuel Suntres
2
,
Myanca Rodrigues
3
,
Logain Alghanemi
4, 5
,
Mohannad Abu-Hilal
4

  1. Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
  2. Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
  3. Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
  4. Division of Dermatology, McMaster University, Hamilton, Ontario, Canada
  5. Dermatology Department, King Abdulaziz University, Jeddah, Saudi Arabia
Adv Dermatol Allergol 2024; XLI (3): 270-275
DOI: https://doi.org/10.5114/ada.2024.141125
Online publish date: 2024/06/30
View full text Get citation
 
Introduction:
Atopic dermatitis (AD) is a chronic inflammatory skin disease with multifactorial pathophysiology. Biologic therapies, including dupilumab (IL-4/IL-13 inhibitor) and tralokinumab (IL-13 inhibitor), as well as selective Janus kinase-1 (JAK-1) inhibitors such as upadacitinib and abrocitinib, have been approved for the treatment of moderate to severe AD. However, their association with the incidence of malignancy in AD patients remains uncertain.

Aim:
We conducted a systematic review and network meta-analysis (NMA) to investigate and compare the indidence and risk of malignancy in individuals with moderate-to-severe AD treated with abrocitinib, upadacitinib, tralokinumab, or dupilumab.

Material and methods:
Systematic searches were conducted in Ovid MEDLINE and EMBASE that included AD, malignancy, biologic and advanced therapies. The primary outcome was incidence of malignancy in AD patients receiving placebo or at least one of the following advanced therapies: dupilumab, tralokinumab, abrocitinib or upadacitinib. A random-effects NMA was conducted with odds ratios and a frequentist model.

Results:
Our search identified 11 trials comprising 10097 patients. The NMA did not show any statistically significant association between dupilumab or selective JAK-1 inhibitors and the incidence of malignancy up to an average of 41 weeks of treatment.

Conclusions:
Our analysis revealed no statistically significant increased risk of malignancy and no significant difference in the incidence of malignancy between selective JAK-1 inhibitors and dupilumab for the treatment of AD up to an average follow-up of 41 weeks. Nevertheless, further prospective studies with longer follow-up periods are warranted to confirm the safety of these therapies and their impact on the risk of malignancy.

keywords:

cancer, malignancy, atopic dermatitis, eczema, dupilumab, Jak-inhibitor, biologic
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.